EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2

Stefan Gahbauer iD, Galen J Correy, Marion Schuller, Matteo P Ferla iD, Yagmur Umay Doruk iD, Moira Rachman iD, Taiasean Wu, Morgan Diolaiti iD, Siyi Wang, R Jeffrey Neitz iD, Daren Fearon iD, Dmytro S Radchenko iD und 10 weitere

Proceedings of the National Academy of Sciences · 10.01.2023 · 120 (2)

DOI: 10.1073/pnas.2212931120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 04.01.2023. Verfasst von Stefan Gahbauer und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 138-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Department of Health, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nonstructural protein 3 (NSP3) of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) contains a conserved macrodomain enzyme (Mac1) that is critical for pathogenesis and lethality. While small-molecule inhibitors of Mac1 have great therapeutic potential, at the outset of the COVID-19 pandemic, there were no well-validated inhibitors for this protein nor, indeed, the macrodomain enzyme family, making this target a pharmacological orphan. Here, we report the structure-based discovery and development of several different chemical scaffolds exhibiting low- to sub-micromolar affinity for Mac1 through iterations of computer-aided design, structural characterization by ultra-high-resolution protein crystallography, and binding evaluation. Potent scaffolds were designed with in silico fragment linkage and by ultra-large library docking of over 450 million molecules. Both techniques leverage the computational exploration of tangible chemical space and are applicable to other pharmacological orphans. Overall, 160 ligands in 119 different scaffolds were discovered, and 153 Mac1-ligand complex crystal structures were determined, typically to 1 Å resolution or better. Our analyses discovered selective and cell-permeable molecules, unexpected ligand-mediated conformational changes within the active site, and key inhibitor motifs that will template future drug development against Mac1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansCrystallographyPandemicsLigandsMolecular Docking SimulationProtease InhibitorsAntiviral Agents

Stichwörter der Autor:innen

coronavirusfragment-based drug discoverymacrodomainvirtual screening

Substanzen

LigandsProtease InhibitorsAntiviral Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
  • Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA 94158.
  • Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.
  • Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • National Institute for Health Research Oxford Biomedical Research Centre, Oxford OX4 2PG, UK.
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158.

ORCID-Profile: Stefan Gahbauer, Matteo P Ferla, Yagmur Umay Doruk, Moira Rachman, Morgan Diolaiti, R Jeffrey Neitz, Daren Fearon, Dmytro S Radchenko, Yurii S Moroz, Adam R Renslo, Jenny C Taylor, Frank von Delft, Brian K Shoichet, James S Fraser

Förderung

  • NIGMS NIH HHS
  • Department of Health
  • Wellcome Trust
  • Biotechnology and Biological Sciences Research Council
  • Cancer Research UK
  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • NSF | BIO | Division of Biological Infrastructure

Zitieren

APA

Gahbauer, S., Correy, G. J., Schuller, M., Ferla, M. P., Doruk, Y. U., Rachman, M., Wu, T., Diolaiti, M., Wang, S., Neitz, R. J., Fearon, D., Radchenko, D. S., Moroz, Y. S., Irwin, J. J., Renslo, A. R., Taylor, J. C., Gestwicki, J. E., von Delft, F., Ashworth, A., …, & Fraser, J. S. (2023). Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2. Proceedings of the National Academy of Sciences, 120(2). https://doi.org/10.1073/pnas.2212931120

Vancouver

Gahbauer S, Correy GJ, Schuller M, Ferla MP, Doruk YU, Rachman M, et al. Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2. Proceedings of the National Academy of Sciences. 2023;120(2). doi:10.1073/pnas.2212931120

BibTeX
@article{Gahbauer2023,
  author = {Gahbauer, Stefan and Correy, Galen J and Schuller, Marion and Ferla, Matteo P and Doruk, Yagmur Umay and Rachman, Moira and Wu, Taiasean and Diolaiti, Morgan and Wang, Siyi and Neitz, R Jeffrey and Fearon, Daren and Radchenko, Dmytro S and Moroz, Yurii S and Irwin, John J and Renslo, Adam R and Taylor, Jenny C and Gestwicki, Jason E and von Delft, Frank and Ashworth, Alan and Ahel, Ivan and Shoichet, Brian K and Fraser, James S},
  title = {Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {2},
  doi = {10.1073/pnas.2212931120}
}
Kostenlos starten →